The stock of Mesa Laboratories, Inc. (NASDAQ:MLAB) reached all time high today, Nov, 24 and still has $140.19 target or 4.00% above today’s $134.80 share price. This indicates more upside for the $498.68 million company. This technical setup was reported by Barchart.com. If the $140.19 PT is reached, the company will be worth $19.95 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock decreased 0.58% or $0.78 on November 23, hitting $134.8. About 19,439 shares traded hands or 65.68% up from the average. Mesa Laboratories, Inc. (NASDAQ:MLAB) has risen 36.33% since April 22, 2016 and is uptrending. It has outperformed by 30.92% the S&P500.
Analysts await Mesa Laboratories, Inc. (NASDAQ:MLAB) to report earnings on February, 7. They expect $0.88 earnings per share, down 4.35% or $0.04 from last year’s $0.92 per share. MLAB’s profit will be $3.26M for 38.30 P/E if the $0.88 EPS becomes a reality. After $0.92 actual earnings per share reported by Mesa Laboratories, Inc. for the previous quarter, Wall Street now forecasts -4.35% negative EPS growth.
According to Zacks Investment Research, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy.”
Insitutional Activity: The institutional sentiment decreased to 1.46 in 2016 Q2. Its down 0.68, from 2.14 in 2016Q1. The ratio fall, as 5 funds sold all Mesa Laboratories, Inc. shares owned while 16 reduced positions. 15 funds bought stakes while 30 increased positions. They now own 1.99 million shares or 2.18% less from 2.04 million shares in 2016Q1.
Neuberger Berman Grp Ltd Limited Liability Company has invested 0% of its portfolio in Mesa Laboratories, Inc. (NASDAQ:MLAB). Metropolitan Life Insurance Ny last reported 0% of its portfolio in the stock. Wasatch Advisors reported 35,685 shares or 0.07% of all its holdings. Morgan Stanley accumulated 0% or 7,434 shares. Group Inc holds 0% or 1,728 shares in its portfolio. Bancshares Of America De holds 0% or 204 shares in its portfolio. Wells Fargo Commerce Mn accumulated 1,341 shares or 0% of the stock. Glenmede Na holds 1,175 shares or 0% of its portfolio. Tompkins Financial Corp accumulated 45 shares or 0% of the stock. Envestnet Asset, a Illinois-based fund reported 1,024 shares. Moreover, Bank Of Montreal Can has 0% invested in Mesa Laboratories, Inc. (NASDAQ:MLAB) for 1,251 shares. Ny State Common Retirement Fund last reported 3,400 shares in the company. Westpac Banking Corp accumulated 5,054 shares or 0% of the stock. The Illinois-based Northern Tru has invested 0% in Mesa Laboratories, Inc. (NASDAQ:MLAB). State Street Corp has invested 0% of its portfolio in Mesa Laboratories, Inc. (NASDAQ:MLAB).
Insider Transactions: Since June 6, 2016, the stock had 0 insider buys, and 4 sales for $1.28 million net activity. CAMPBELL H STUART sold $476,080 worth of Mesa Laboratories, Inc. (NASDAQ:MLAB) on Friday, October 21. Sakys John also sold $127,140 worth of Mesa Laboratories, Inc. (NASDAQ:MLAB) shares. Another trade for 3,000 shares valued at $335,220 was made by Adriance Glenn E on Monday, June 6.
More news for Mesa Laboratories, Inc. (NASDAQ:MLAB) were recently published by: Marketwatch.com, which released: “Mesa Laboratories downgraded to neutral from buy at Sidoti & Co.” on April 21, 2011. Quotes.Wsj.com‘s article titled: “News Mesa Laboratories Inc.MLAB” and published on February 11, 2011 is yet another important article.
MLAB Company Profile
Mesa Laboratories, Inc., incorporated on March 26, 1982, is focused primarily on quality control services and products. The Firm operates through four divisions: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, makes and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. The Company’s Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. The Company’s Continuous Monitoring Division designs, develops and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity and differential pressure in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and various other laboratory and industrial environments. The Company’s Cold Chain Division provides parameter (primarily temperature) monitoring of products in a cold chain, consulting services, such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products, such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.